Cargando…

Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study

BACKGROUND: Cardiac biomarkers may signal mechanistic pathways involved in heart failure (HF), a leading complication in chronic kidney disease. We tested the associations of NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity troponin T (hsTnT), galectin‐3, growth differentiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Nisha, Zelnick, Leila, Go, Alan, Anderson, Amanda, Christenson, Robert, Deo, Rajat, Defilippi, Christopher, Lash, James, He, Jiang, Ky, Bonnie, Seliger, Stephen, Soliman, Elsayed, Shlipak, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898812/
https://www.ncbi.nlm.nih.gov/pubmed/31645163
http://dx.doi.org/10.1161/JAHA.119.012336
_version_ 1783477031463288832
author Bansal, Nisha
Zelnick, Leila
Go, Alan
Anderson, Amanda
Christenson, Robert
Deo, Rajat
Defilippi, Christopher
Lash, James
He, Jiang
Ky, Bonnie
Seliger, Stephen
Soliman, Elsayed
Shlipak, Michael
author_facet Bansal, Nisha
Zelnick, Leila
Go, Alan
Anderson, Amanda
Christenson, Robert
Deo, Rajat
Defilippi, Christopher
Lash, James
He, Jiang
Ky, Bonnie
Seliger, Stephen
Soliman, Elsayed
Shlipak, Michael
author_sort Bansal, Nisha
collection PubMed
description BACKGROUND: Cardiac biomarkers may signal mechanistic pathways involved in heart failure (HF), a leading complication in chronic kidney disease. We tested the associations of NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity troponin T (hsTnT), galectin‐3, growth differentiation factor‐15 (GDF‐15), and soluble ST2 (sST2) with incident HF in chronic kidney disease. METHODS AND RESULTS: We examined adults with chronic kidney disease enrolled in a prospective, multicenter study. All biomarkers were measured at baseline. The primary outcome was incident HF. Secondary outcomes included HF with preserved ejection fraction (EF≥50%) and reduced ejection fraction (EF<50%). Cox models were used to test the association of each cardiac biomarker with HF, adjusting for demographics, kidney function, cardiovascular risk factors, and medication use. Among 3314 participants, all biomarkers, with the exception of galectin‐3, were significantly associated with increased risk of incident HF (hazard ratio per SD higher concentration of log‐transformed biomarker): NT‐proBNP (hazard ratio, 2.07; 95% CI, 1.79–2.39); hsTnT (hazard ratio, 1.38; 95% CI, 1.21–1.56); GDF‐15 (hazard ratio, 1.44; 95% CI, 1.26–1.66) and sST2 (hazard ratio, 1.19; 95% CI, 1.05–1.35). Higher NT‐proBNP, hsTnT, and GDF‐15 were also associated with a greater risk of HF with reduced EF; while higher NT‐proBNP GDF‐15 and sST2 were associated with HF with preserved EF. Galectin‐3 was not associated with either HF with reduced EF or HF with preserved EF. CONCLUSIONS: In chronic kidney disease, elevations of NT‐proBNP, hsTnT, GDF‐15, sST2 were associated with incident HF. There was a borderline association of galectin‐3 with incident HF. NT‐proBNP and hsTnT were more strongly associated with HF with reduced EF, while the associations of the newer biomarkers GDF‐15 and sST2 were stronger for HF with preserved EF.
format Online
Article
Text
id pubmed-6898812
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68988122019-12-16 Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study Bansal, Nisha Zelnick, Leila Go, Alan Anderson, Amanda Christenson, Robert Deo, Rajat Defilippi, Christopher Lash, James He, Jiang Ky, Bonnie Seliger, Stephen Soliman, Elsayed Shlipak, Michael J Am Heart Assoc Original Research BACKGROUND: Cardiac biomarkers may signal mechanistic pathways involved in heart failure (HF), a leading complication in chronic kidney disease. We tested the associations of NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity troponin T (hsTnT), galectin‐3, growth differentiation factor‐15 (GDF‐15), and soluble ST2 (sST2) with incident HF in chronic kidney disease. METHODS AND RESULTS: We examined adults with chronic kidney disease enrolled in a prospective, multicenter study. All biomarkers were measured at baseline. The primary outcome was incident HF. Secondary outcomes included HF with preserved ejection fraction (EF≥50%) and reduced ejection fraction (EF<50%). Cox models were used to test the association of each cardiac biomarker with HF, adjusting for demographics, kidney function, cardiovascular risk factors, and medication use. Among 3314 participants, all biomarkers, with the exception of galectin‐3, were significantly associated with increased risk of incident HF (hazard ratio per SD higher concentration of log‐transformed biomarker): NT‐proBNP (hazard ratio, 2.07; 95% CI, 1.79–2.39); hsTnT (hazard ratio, 1.38; 95% CI, 1.21–1.56); GDF‐15 (hazard ratio, 1.44; 95% CI, 1.26–1.66) and sST2 (hazard ratio, 1.19; 95% CI, 1.05–1.35). Higher NT‐proBNP, hsTnT, and GDF‐15 were also associated with a greater risk of HF with reduced EF; while higher NT‐proBNP GDF‐15 and sST2 were associated with HF with preserved EF. Galectin‐3 was not associated with either HF with reduced EF or HF with preserved EF. CONCLUSIONS: In chronic kidney disease, elevations of NT‐proBNP, hsTnT, GDF‐15, sST2 were associated with incident HF. There was a borderline association of galectin‐3 with incident HF. NT‐proBNP and hsTnT were more strongly associated with HF with reduced EF, while the associations of the newer biomarkers GDF‐15 and sST2 were stronger for HF with preserved EF. John Wiley and Sons Inc. 2019-10-24 /pmc/articles/PMC6898812/ /pubmed/31645163 http://dx.doi.org/10.1161/JAHA.119.012336 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Bansal, Nisha
Zelnick, Leila
Go, Alan
Anderson, Amanda
Christenson, Robert
Deo, Rajat
Defilippi, Christopher
Lash, James
He, Jiang
Ky, Bonnie
Seliger, Stephen
Soliman, Elsayed
Shlipak, Michael
Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
title Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
title_full Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
title_fullStr Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
title_full_unstemmed Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
title_short Cardiac Biomarkers and Risk of Incident Heart Failure in Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study
title_sort cardiac biomarkers and risk of incident heart failure in chronic kidney disease: the cric (chronic renal insufficiency cohort) study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898812/
https://www.ncbi.nlm.nih.gov/pubmed/31645163
http://dx.doi.org/10.1161/JAHA.119.012336
work_keys_str_mv AT bansalnisha cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT zelnickleila cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT goalan cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT andersonamanda cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT christensonrobert cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT deorajat cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT defilippichristopher cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT lashjames cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT hejiang cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT kybonnie cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT seligerstephen cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT solimanelsayed cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT shlipakmichael cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy
AT cardiacbiomarkersandriskofincidentheartfailureinchronickidneydiseasethecricchronicrenalinsufficiencycohortstudy